New weekly shot aims to tame type 1 diabetes alongside insulin pumps

NCT ID NCT06630585

Summary

This study is testing if adding a once-weekly medication called tirzepatide to automated insulin pump therapy helps adults with type 1 diabetes manage their blood sugar better. Researchers will compare the new combination to standard insulin pump therapy alone in 42 participants over 12 weeks. The main goal is to see if people spend more time in a healthy blood sugar range and can reduce their total daily insulin dose.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES (T1D) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • DiaCenTRE - Hirslanden Clinique des Grangettes

    RECRUITING

    Chêne-Bougeries, Canton of Geneva, 1224, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Kantonsspital Olten

    RECRUITING

    Olten, Canton of Solothurn, 4600, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Luzerner Kantonspital

    RECRUITING

    Lucerne, 6000, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.